Isabelle M Gorrillot, PhD
Co-founder, CEO
HO2Rx
Doylestown, United States
At Ho2Rx we pioneer a game-changing therapy to safely and durably treat intractable chronic inflammatory diseases by targeting inflammation-damaged tissues.
My organisation
About me
Dr. Isabelle M. Gorrillot brings more than 30 years of experience in biotechnology business development, licensing, and early-stage investment. In 2024, she co-founded HO2Rx, a pre-seed biotechnology venture, and serves as its fractional CEO, advancing therapeutics for chronic inflammatory diseases affecting millions of patients. The venture exemplifies her dual focus on scientific innovation and strategic entrepreneurship, combining breakthrough research with innovative corporate strategy to maximize impact and growth.
Dr. Gorrillot has contributed to numerous strategic partnerships, company-building initiatives, and scientific programs with significant potential deal value and health impact. She earned peer recognition for both her professional achievements and strong business ethics as Trustee of the Licensing Executives Society (LES) USA & Canada, and has led academia-industry partnering workshops. She reviews NIH SBIR/STTR grants, mentors early-career investigators and entrepreneurs, and advises the European Investment Bank (EIB) as a Technical Expert on scale-up investments.
A Pasteur-trained immunologist, Dr. Gorrillot’s strong scientific foundation has enabled her to translate a broad range of medical innovations into game-changing therapeutics across multiple disease areas. Outside her professional activities, she is an avid equestrian and horse lover, as well as an outdoor enthusiast who enjoys whitewater kayaking and hiking in the mountains.